Abstract: Systems and methods are disclosed to optimize resources of a medical device system, including to analyze physiologic information of a patient occurring over specific time periods relative to a prior heart failure event, to adjust, in response to a detected or received trigger event, a baseline value for the patient from a long-term baseline value to one of a shorter-term baseline value or a static value indicative of a baseline value at a prior time relative to the detected or received trigger event, to determine a readmission score for the patient based on the analyzed physiologic information, and to provide a control signal to control a mode or operation of the medical device system based on the readmission score to optimize resources of the medical device system.

Abstract: A medical device system includes an ambulatory medical device and a second device. The ambulatory medical device includes one or more physiologic sensors configured to output sensor data and a communication circuit to transmit the sensor data to another device. The second device includes another communication circuit configured to receive the sensor data from ambulatory medical device, and processing circuitry. The processing circuitry is configured to determine patterns of the sensor data consistent with hemodialysis treatments of the patient, identify a change in the patterns of the sensor data indicative of a change in the hemodialysis treatments, and produce an alert associated with the hemodialysis treatments in response to the determining the change in the patterns of the sensor data.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: Systems and methods to provide remote patient monitoring for viral-respiratory symptoms, including coronavirus or COVID-19 symptoms are disclosed, including a signal receiver circuit configured to receive first and second physiologic information of a patient, the first physiologic information comprising respiration rate information of a patient and the second physiologic information different than the first physiologic information, and an assessment circuit configured to determine an indication of patient viral-respiratory disease using the received first and second physiologic information.

Abstract: Systems and methods for detecting a physiological event or estimating a physiological parameter using ambulatory electrograms of a subject are discussed. An exemplary system includes a computing device that can receive ambulatory electrograms collected by an ambulatory medical device (AMD) associated with a subject, and apply the ambulatory electrograms to a trained machine learning model to estimate a physiological parameter or to detect a physiological event in the subject. The same or a different machine learning model can be trained to detect an operating status of the AMD using the ambulatory electrograms. The system comprises an output device to output the estimated physiological parameter, the detected physiological event, or the detected device operating status a user or a process such as to initiate or titrate a therapy.

Abstract: Systems and methods to provide remote patient monitoring for viral-respiratory symptoms, including coronavirus or COVID-19 symptoms are disclosed, including a signal receiver circuit configured to receive first and second physiologic information of a patient, the first physiologic information comprising respiration rate information of a patient and the second physiologic information different than the first physiologic information, and an assessment circuit configured to determine an indication of patient viral-respiratory disease using the received first and second physiologic information.

Abstract: An example of a system includes a blood pressure modulation device and a controller. The blood pressure modulation device may be configured to deliver a therapy to chronically maintain blood pressure within a prescribed range. The blood pressure modulation device may include a neuromodulator configured to deliver neuromodulation energy to neural tissue in a spinal cord or near the spinal cord using a first parameter set. The controller may include analyzer circuitry configured to determine an actual or anticipated blood pressure demand event indicated for a blood pressure change, and therapy parameter adjuster circuitry configured to respond to the actual or anticipated blood pressure demand event by delivering neuromodulation energy using a second parameter set to change the blood pressure.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.

Abstract: An example of a system for modulating blood pressure may include a blood pressure monitoring circuit, a blood pressure modulation device, and a control circuit. The blood pressure monitoring circuit may be configured to sense signals and generate one or more blood pressure parameters indicative of the blood pressure and/or a vascular resistance and one or more activity parameters indicative of an activity level and/or a postural change using the sensed signals. The blood pressure modulation device may be configured to deliver a therapy modulating the blood pressure. The control circuit may be configured to control the therapy using therapy parameters, receive the one or more blood pressure parameters and the one or more activity parameters, analyze changes in the one or more blood pressure parameters that are correlated to changes in the one or more activity parameters, and adjust the therapy parameters using an outcome of the analysis.

Abstract: An example of a system includes a blood pressure modulation device and a controller. The blood pressure modulation device may be configured to deliver a therapy to chronically maintain blood pressure within a prescribed range. The blood pressure modulation device may include a neuromodulator configured to deliver neuromodulation energy to neural tissue in a spinal cord or near the spinal cord using a first parameter set. The controller may include analyzer circuitry configured to determine an actual or anticipated blood pressure demand event indicated for a blood pressure change, and therapy parameter adjuster circuitry configured to respond to the actual or anticipated blood pressure demand event by delivering neuromodulation energy using a second parameter set to change the blood pressure.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A system for monitoring autonomic health may include an autonomic nerve stimulation (ANS) dose delivery system and a response extractor. The response extractor may be configured to record physiological parameter values including first population data that includes evoked response (ER) values corresponding to evoked physiological responses, and second population data that includes reference values that include no effect (NE) values corresponding to times without a physiological response. The response monitor may calculate evoked response metrics (ERMs) using the first and second population data where each of the ERMs may be dependent on background autonomic activity. The response extractor may analyze the ERMs to provide ERM analysis, and provide an indication of autonomic health using the ERM analysis.

Abstract: A method may include delivering autonomic neural stimulation (ANS) therapy, including delivering stimulation pulses to evoke physiological responses. The method may further include recording physiological parameter values, including recording first population data, the first population data including evoked response (ER) values corresponding to the evoked physiological responses, and recording second population data, the second population data including reference values that include no effect (NE) values corresponding to times without an evoked physiological response. The method may further include quantifying a relationship between the first population data and the second population data, and analyzing the quantified relationship for a signature to indicate if the stimulation pulses are evoking desired physiological responses.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: An example of a system for modulating blood pressure may include a blood pressure monitoring circuit, a blood pressure modulation device, and a control circuit. The blood pressure monitoring circuit may be configured to sense signals and generate one or more blood pressure parameters indicative of the blood pressure and/or a vascular resistance and one or more activity parameters indicative of an activity level and/or a postural change using the sensed signals. The blood pressure modulation device may be configured to deliver a therapy modulating the blood pressure. The control circuit may be configured to control the therapy using therapy parameters, receive the one or more blood pressure parameters and the one or more activity parameters, analyze changes in the one or more blood pressure parameters that are correlated to changes in the one or more activity parameters, and adjust the therapy parameters using an outcome of the analysis.

Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.

Abstract: A system for monitoring autonomic health may include an autonomic nerve stimulation (ANS) dose delivery system and a response extractor. The response extractor may be configured to record physiological parameter values including first population data that includes evoked response (ER) values corresponding to evoked physiological responses, and second population data that includes reference values that include no effect (NE) values corresponding to times without a physiological response. The response monitor may calculate evoked response metrics (ERMs) using the first and second population data where each of the ERMs may be dependent on background autonomic activity. The response extractor may analyze the ERMs to provide ERM analysis, and provide an indication of autonomic health using the ERM analysis.